- Scientific research suggests some mushrooms can provide mental benefits, anti-tumor effects, improved immune function, anti-viral properties and detoxification
- “Psychedelic” varieties currently being studied for depression, anxiety, PTSD, bipolar disorder, Alzheimer’s disease, addiction
- Pure Extracts is expanding into functional mushroom market; Company is currently licensed by Health Canada to buy, sell, produce cannabis products
Mushrooms have been used for thousands of years in Eastern medicine to combat illness, increase mental cognition and improve digestion. As their popularity continues to increase worldwide, Pure Extract Technologies, a privately held, plant-based, Canadian extraction company is leveraging the growing acceptance by mainstream science and the general public to further develop and commercialize functional and medicinal mushroom products on a global scale.
Described by world-renowned mycologist Paul Stamets as “nature’s miniature pharmaceutical factories” (https://cnw.fm/eMZyO), mushrooms have been studied extensively by mainstream science for their various health benefits. Current research has suggested that some varieties such as Hericum Erinaceus or “lion’s mane” can help improve memory (https://cnw.fm/NxpuW) and mental cognition (https://cnw.fm/x3k7O) in addition to improving the symptoms of depression (https://cnw.fm/7sIik).
“Psychedelic” varieties such as psilocybin – or “magic mushrooms” – are increasingly being studied for possible medical benefits in treating depression, anxiety, PTSD, bipolar disorder, Alzheimer’s disease and addiction. UC Berkeley recently unveiled the UC Berkeley Center for the Science of Psychedelics (https://cnw.fm/gL3yd) with the aim of studying psilocybin for mental benefits in addition to other properties that include anti-tumor effects, improved immune function, anti-viral properties and detoxification. The FDA granted psychedelics breakthrough therapy status for treatment-resistant depression in 2020 with approvals expected in 2021 (https://cnw.fm/rqKqL), making therapy options possible in the very near future.
Pure Extracts has a solid position in the industry to partner with organizations in the sourcing, production and development of functional mushroom products and to advance its mushroom extraction techniques in order to produce, consistent, ultra-pure, compounds. Besides being licensed by Health Canada to buy, sell and produce cannabis products, the Company’s 10,000 square foot facility is designed for EU-GMP certification, which will allow Pure Extracts to sell its products throughout the world.
Along with mushrooms, Pure Extracts’ business model comprises three additional verticals that include in-house brand marketing, raw cannabis & hemp conversion into marketable products and white labeling services that supply products to other Licenced Producers. In addition to signing NDAs to explore joint development endeavors, the Company also has an advisory agreement with Dr. Alexander MacGregor, the founder of the Toronto Institute of Pharmaceutical Technology (“TIPT”), a provider of clinical trial services through its fully compliant Health Canada licensed Good Manufacturing Practice (“GMP”) manufacturing and testing facility.
The psychedelic and functional mushroom industry is currently in a transitory phase whereby dry biomass is being converted to extracts. This changing landscape is positioning Pure Extracts to emerge as a leader in the industry, allowing the Company to benefit from the growing acceptance of mushroom extracts by the scientific community and general public.
For more information, visit the company’s website at www.PureExtractsCorp.com.
NOTE TO INVESTORS: The latest news and updates relating to Pure Extract Technologies are available in the company’s newsroom at http://cnw.fm/Pure
CannabisNewsWire (CNW) is an information service that provides (1) access to our news aggregation and syndication servers, (2) CannabisNewsBreaks that summarize corporate news and information, (3) enhanced press release services, (4) social media distribution and optimization services, and (5) a full array of corporate communication solutions. As a multifaceted financial news and content distribution company with an extensive team of contributing journalists and writers, CNW is uniquely positioned to best serve private and public companies that desire to reach a wide audience of investors, consumers, journalists and the general public. CNW has an ever-growing distribution network of more than 5,000 key syndication outlets across the country. By cutting through the overload of information in today’s market, CNW brings its clients unparalleled visibility, recognition and brand awareness. CNW is where news, content and information converge.
To receive instant SMS alerts, text CANNABIS to 21000 (U.S. Mobile Phones Only)
For more information please visit https://www.CannabisNewsWire.com
Do you have questions or are you interested in working with CNW? Ask our Editor
CannabisNewsWire is part of the InvestorBrandNetwork.